Search

Tisagenlecleucel

It was granted approval by FDA in August 2017 under the market name Kymriah. … Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric

Duvelisib

can produce a broad adaptative and innate immune cell inhibitory activity. … All the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]

IL15-NK Cell

In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to. … Natural killer (NK) cells can be incubated with ‘feeder cells’ expressing certain cytokines prior to maturation to enhance their activity.

Strontium chloride Sr-89

It is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. … Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer.[A31264] Bone metastases is a common and severe complication presented in advanced stages of the disease.

Bacillus calmette-guerin substrain russian BCG-I live antigen

thought to work by stimulating a local immune and inflammatory response in the bladder. … [L32734] It is to be marketed by Verity Pharmaceuticals, under the trade name VERITY-BCG, and manufactured by the Serum Institute of India.

Gemeprost

It is not FDA-approved but available in Japan marketed as Preglandin. … It is available as vaginal suppositories and also used in combination with the antiprogestin and mifepristone for termination of 1st- and 2nd-trimester pregnancy [A19726].

Oxethazaine

[A33104] Oxetacaine is approved by Health Canada since 1995 for its use as an antacid combination in over-the-counter preparations. … [L1113] It is also in the list of approved derivatives of herbal products by the EMA.[L2816]

Ephedra sinica stem

Relugolix

It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name … [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management